MapLight Therapeutics (MPLT) Depreciation & Amortization (CF) (2024 - 2025)

MapLight Therapeutics' (MPLT) quarterly Depreciation & Amortization (CF) came in at $140000.0 in Q4 2025, down 30.0% year-on-year from $200000.0 in Q4 2024, and up 40.0% quarter-over-quarter from $100000.0 in Q3 2025.

MapLight Therapeutics (MPLT) Depreciation & Amortization (CF) (2024 - 2025) Analysis & Trends

MapLight Therapeutics has disclosed Depreciation & Amortization (CF) across 2 years of filings, most recently posting $140000.0 for Q4 2025.

  • Depreciation & Amortization (CF) for Q4 2025 came in at $140000.0, down 30.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $640000.0 (changed N/A YoY), and the FY2025 annual result was $578000.0, down 17.43% from the prior year.
  • Depreciation & Amortization (CF) came in at $140000.0 for Q4 2025 at MapLight Therapeutics, up from $100000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $200000.0 in Q3 2024 to a low of $100000.0 in Q3 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - 1,395.22
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -1,330.00
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 55.90 Mn
9 Abivax 91.96 Bn 91.96 Bn - 429,663.65
10 MapLight Therapeutics 248.88 Mn 248.88 Mn - 140,000.00

Historic Data

Download Data
DateValue
Dec 31, 2025 140,000.00
Dec 31, 2025 140,000.00
Sep 30, 2025 100,000.00
Sep 30, 2025 100,000.00
Dec 31, 2024 200,000.00
Dec 31, 2024 200,000.00
Sep 30, 2024 200,000.00
Sep 30, 2024 200,000.00